Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' [Yahoo! Finance]
Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? [Yahoo! Finance]
Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community [Yahoo! Finance]